2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 212

Rising Incidence and Prevalence of Gout in the Canadian General Population
Abstract Number: 2249

Risk and Risk Perception of Knee Osteoarthritis in the US: Population-Based Study
Abstract Number: 2197

Risk Factors for Adverse Pregnancy Outcome in First-Line Treated Pregnancies in Antiphospholip Antibodies-Positive Women According to Different Treatment Protocols: A Single Center Experience over 30 Years
Abstract Number: 1844

Risk Factors for Complicated Pneumonia in Systemic Lupus Erythematosus (SLE)
Abstract Number: 868

Risk Factors for Cytomegalovirus Reactivation in Patients with Antineutrophil Cytoplasmic Antibody -Associated Vasculitis
Abstract Number: 2940

Risk Factors for Late-Onset Thrombosis in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1359

Risk Factors for the Development of Gout in HIV Patients: A Retrospective Study
Abstract Number: 616

Risk Factors for the Exacerbation of Interstitial Lung Disease (ILD) after Administration of Biologic Dmards in RA Patients with Pre-Existing ILD
Abstract Number: 2051

Risk for Lower Intestinal Perforations in RA Patients Treated with Tocilizumab in Comparison to Treatment with TNF Inhibitors, Rituximab, Abatacept or Conventional Synthetic Dmards
Abstract Number: 32

Risk for Lung Cancer in RA and Different RA Phenotypes: Results from a Population-Based Case-Control Study
Abstract Number: 2141

Risk of Cancer in Non-TNFi Biologics-Treated RA
Abstract Number: 1956

Risk of Cerebrovascular Accident in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis
Abstract Number: 31

Risk of Chronic Obstructive Pulmonary Disease in Rheumatoid Arthritis: A Population Based Cohort Study
Abstract Number: 610

Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Treated with Biologic Disease-Modifying Therapy Compared with Conventional Therapy
Abstract Number: 2244

Risk of Incident Atrial Fibrillation in Gout

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].